Novo Holdings cuts MapLight stake to 4.9%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Novo Holdings A/S filed an amendment reporting its ownership in MapLight Therapeutics, Inc. It beneficially owns 2,086,622 shares of voting common stock, representing 4.9% of MapLight’s outstanding common shares, based on 42,618,165 shares outstanding as of May 7, 2026.
On July 30, 2026, Novo Holdings sold MapLight shares in open market transactions, including 1,314,195 shares at $12.00 per share and additional blocks at weighted-average prices of $14.19 and $14.69. As of that date, the reporting persons ceased to be beneficial owners of more than five percent of MapLight’s common stock.
Key Figures
Key Terms
beneficially owns financial
Sole Voting Power financial
Sole Dispositive Power financial
open market transactions financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership in MapLight Therapeutics (MPLT) does Novo Holdings report in this amendment?
When did Novo Holdings cease to be a more-than-5% owner of MapLight (MPLT)?
What percentage of MapLight (MPLT) does Novo Holdings’ current stake represent?
AI-generated analysis. How Rhea-AI works. Not financial advice.